

Design Verification of Ypsomed's On Body Delivery System (OBDS) according ISO 11608 utilizing the support of ZwickRoell

Christian Esser Wiesemann, Ypsomed AG 17.10.2023





Agenda

- 1. Ypsomed company overview
- 2. YpsoDose a patient-centric On Body Device System (OBDS) marketview
- 3. Required norms for Design Verification of electromechatronical devices
- 4. Which tests applied for YpsoDose based on ISO11608?
- 5. Support on Design Verification of OBDS 11608 based on Zwick Roell equipment?
- 6. Interpretation and additional tests on new 11608:6-2022
- 7. Outlook on Batch Release process
- 8. Critical reflection





Ypsomed - Vision and mission


- Vision Ypsomed solutions make selfcare simpler and easier.
- Mission With innovative, simple-to-use and reliable products as well as modern care concepts, we contribute significantly to the success of a therapy and thereby enable people to enjoy the best possible quality of life.
- 2'200 employees ww HQ Switzerland
- 500m CHF turnover p.a.








Ypsomed – company overview





YpsoDose a patient centric OBDS - marketview

- Market potential >100 assets in development with a volume >2.25ml
- Market development of 5.5ml
 Autoinjectors are influencing the OBDS market
- Demand on OBDS in today's HCP setting (oncology today mainly with syringe) – hometreatment?
- Highly competitive landscape in OBDS market shapes market situation and design



Source: Pharma big pharma pipeline Analysis August 2023 Ypsomed internal analysis









OBDS vs. Autoinjector





Ypsomed core business



Difference in «functions» which needs to be proven in Design Verification according ISO 11608-2022 of a combination product

> LED's vs. No LED's Motor Driven vs. Spring Driven Buzzer Sounds vs. Mechanical Clicks Adhesion force to skin vs. Manually applied onto skin Injection up to 30minutes vs. Injection under 10-30s





Ypsomed's laboratory requirements & standards to perform **DV** on Autoinjectors

Ypsomed performs multiple Design Verification tests with autoinjectors p.a.

- Automatization to ensure repeatable test execution
- High accuracy requirement on standardized documentation of test
- Minimized human error potential of test procedure
- Check multiple test attributes with one test execution – less devices and ressources needed

Tests to be documented with limited human influence and with high accuracy

Test & raw-data of test system (video, audio) availability to ensure traceability and analysis








Support on Design Verification of OBDS 11608 based on **Zwick Roell equipment?**

What was the challenge to enroll YpsoDose Design Verification test with Zwick Roell equipment:


- **Primary functions** can be tested / captured in one test set-up
- Machine **perform tests autonomous** (injection time >20minutes)
- Partner and ability to learn from each **other** – as no standard of testing from **OBDS** existed
- Build a **solution**, which works also **for** pharmapartners to release their combination product (YpsoDose + primary packaging filled with drug product)







Norms/interpretations for Design Verification of on-body devices - ISO 11608 and FDA feedback







Norms for Design Verification of on-body devices

Example interpretation of 11608-1:2022 for YpsoDose

Primary function

- Dose accuracy of drug delivered
- Delivery time of drug injection
- Needle extension

*

Essential Performance Requirements per FDA feedback to Ypsomed

- Dose accuracy (primary function)
- Injection Time (primary function)
- Needle Extension (primary function)
- Actuation force
- Visual / audible feedback
- Delivery profile (flow rate)
- Skin needle retraction

*


All tests conducted under all pre-conditions (warm, cold, ...)



^{*} list is not exhaustive



Let's review the results I



YPS@MED

Test Report

Competence Center Laboraory Brunnmattstrasse 6 CH-3401 Burgdorf

Test results

Legende	Nr	Datum/Zeit	Fb N	Lne mm	dVol/dt _{max} ml/min	Vol. ml	Del. time min	t _{Ges} min	Lne _{Ende}
	max								
	min								
	1	09.06.2023 07:39:45	3.6	6.08	0.411	6.096	16.344	21.91	Ok
	2	09.06.2023 08:17:23	3.7	6.08	0.408	6.113	16.476	21.88	Ok
•	3	09.06.2023 09:00:36	3.6	6.16	0.410	6.171	16.672	21.60	Ok
	4	09.06.2023 09:56:10	3.6	6.16	0.410	6.132	16.427	22.14	Ok
	5	09.06.2023 10:44:10	3.6	6.22	>0.436	6.180	19.324	22.17	Ok

Statistics

Sei	rie	Fb	Lne	dVol/dt _{max}	Vol.	Del. time	tGes
n =	= 5	N	mm	ml/min	ml	min	min
)	K	3.6	6.14	0.415	6.138	17.049	21.94
m	in	3.6	6.08	0.408	6.096	16.344	21.60
m	ax	3.7	6.22	0.436	6.180	19.324	22.17
9	5	0.0	0.06	0.012	0.036	1.278	0.23

Expanded statistics

Inspected:

	Buttonforce	Injektionstiefe	Flowrate	Volume	Delivery Time	Overall Injection Time
р	99.0%	97.5%	95.0%	97.5%	97.5%	97.5%
k	6.598	5.774	4.203	4.909	4.909	6.015
Ø+k·s	3.915 N	6.486 mm	0.464 ml/min			23.213 min
Ø-k·s	3.325 N	5.794 mm		5.96 ml	10.776 min	

	ID:	Date:	Signature:
Created:			





Let's review the results II

Essential Performance Requirements per FDA feedback to Ypsomed

- Dose accuracy (primary function) 1
- Injection Time (primary function) (first-drop to last) 2
- Needle Extension (primary function) 3
- Actuation force 4
- Visual / audible feedback 5
- Delivery profile (flow rate) 6
- Skin needle retraction 7

additionally to the test-report each injectionvideo (LED feedback, buzzer sound) is captured and stored to the test



Test Report

Competence Center Laboraory Brunnmattstrasse 6

Test results

		Datum/Zeit	Fb	Lne	$dVol/dt_{max}$	Vol.	Del. time	t_{Ges}	Lne _{Ende}
Legende	Nr		N	mm	ml/min	ml	min	min	
	max								7
	min								
•	1	09.06.2023 07:39:45	3.6	6.08	0.411	6.096	16.344	21.91	Ok
	2	09.06.2023 08:17:23	3.7	6.08	0.408	6.113	16.476	21.88	Ok
•	3	09.06.2023 09:00:36	3.6	6.16	0.410	6.171	16.672	21.60	Ok
•	4	09.06.2023 09:56:10	3.6	6.16	0.410	6.132	16.427	22.14	Ok
•	5	09.06.2023 10:44:10	3.6	6.22	>0.436	6.180	19.324	22.17	Ok

Statistics

Serie	Fb	Lne	dVol/dt _{max}	Vol.	Del. time	tGes	ξ
n = 5	N	mm	ml/min	ml	min	min	Y
x	3.6	6.14	0.415	6.138	17.049	21.94	Ι
min	3.6	6.08	0.408	6.096	16.344	21.60]
max	3.7	6.22	0.436	6.180	19.324	22.17]
s	0.0	0.06	0.012	0.036	1.278	0.23	1

Expanded statistics

k 4 6.598 5.574 4 4.203 4.4909 2 4.909 6.0 3.915 N 6.486 mm 0.464 ml/min 23.213 n 0-ks 3.325 N 5.794 mm		But	tonforce	Injektio	onstiefe	F	lowrate	١	/olume	Delive	ry Time	Overall Injection Time
0.535 N 6.486 mm 0.464 ml/min 23.213 n Ø-ks 3.325 N 5.794 mm 5.96 ml 10.776 min	р	1	99.0%	2	97.5%	6	95.0%	1	97.5%	9	97.5%	97.5%
Ø-k·s 3.325 N 5.794 mm 5.96 ml 10.776 min	k	4	6.598	J	5.774		4.203		4.909	4	4.909	6.015
	Ø+k·s		3.915 N	6.4	86 mm	0.464	ml/min					23.213 min
Paguit	Ø-k·s		3.325 N	5.7	'94 mm				5.96 ml	10.7	776 min	
Result	Result											(
omments:	omm	ent	s:									

	ID:	Date:	Signature:
Created:			
Inspected:			

YpsoDose DV Tests are tested on Zwick-Roell equipment and capture 98% of all relevant tests according ISO 11608 incl. FDA relevant Essential Performance Requirements



^{*} list is not exhaustive



How to interpret ISO11608:6-2022 – OBDS section

ISO11608:6 refers especially on the Design Verification of OBDS specialties:

Adhesive

Freedom of Orientation

Dose Delivery Profiles if clinically relevant

GAP interpretation of chapter 6 according to the Ypsomed processhouse on ISO11608 shows following additional considerations on combination product level:

- 1. Orientational worst-case testing
- 2. Adhesive testing
- 3. Exposure to typical fluids
- Dose delivery profiles (only if clinically relevant)



^{*} list is not exhaustive





Outlook on Batch Release process

Pharma Companies are required to test the **primary function** of the combination product for every batch release.

Ypsomed believes, that the the joined development will support pharma companies in their release process of combination products of OBDS.











Critical reflection on Design Verification of Ypsomed's on-bodyinjector according ISO 11608 utilizing the support of ZwickRoell

Ypsomed can provide evidence to pharma companies about majority of conducted tests on 11608 using support of ZwickRoell.

Minority of required tests remain manually performed due to orientation and other test requirements.

Handling of Testequipment is manual (loading, etc.) which shows potential for automatisation for high volume.

Generated test reports from support of ZwickRoell are used not only for 11608 Design Verification tests also within Feasibility studies to ensure reproducable testing results.

Joined testing strategy at Ypsomed and pharma partners supports quality of combination product.

Thanks Zwick Roell for the great collaboration!





More confidence. More success. With Ypsomed Delivery Systems.







Autoinjector systems



Patch injector systems



Smart services

